Skip to main content

Dr. Alan L. Lee, M.D.

Family Medicine (Family Medicine Physician)

  • Medicare participating

At a glance

Years since graduation
30
In the NPI registry since
2006
Medicare patients seen, 2024
597

Licensed in Texas since 1999, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1996Medical school: University of Texas Medical Branch at Galveston
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Family Medicine Physician primary
    TX license K8283 (first issued 1999; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Family Medicine per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
597
Services billed
5,652
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes813457
Established patient office or other outpatient visit, 20-29 minutes742405
Blood test, comprehensive group of blood chemicals325238
Hemoglobin a1c level317202
Blood test, lipids (cholesterol and triglycerides)309235
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit282282
Management using the results of remote vital sign monitoring per calendar month, first 20 minutes19723
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count195157
Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days17121
Advance care planning, first 30 minutes129128

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 1 payments worth $15.98 in total to this clinician.

By company
Medtronic, Inc.$15.98
By type
Food and Beverage$15.98

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 12 industry-funded studies in 2025, from 8 companies. The companies reported $1,035,258 in research payments for these studies, mostly to the institutions running them.

  • A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
    ModernaTX, Inc. · Completed · NCT06602024
  • A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clini…
    AstraZeneca Pharmaceuticals LP
  • A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
    Sanofi US Services Inc. · Active, not recruiting · NCT06676319
  • TRANSFORM
    Cleerly, Inc.
  • A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
    Boehringer Ingelheim Pharma GmbH & Co.kg
  • A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
    Novartis Pharmaceuticals Corporation
  • A Phase 2 Randomized Doubleblind Placebo-controlled Doseranging Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of AZD0780 in Participants with Dyslipidemi
    AstraZeneca Pharmaceuticals LP
  • A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
    Boehringer Ingelheim International GmbH

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Family Medicine clinicians in San Marcos

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 19, 2009), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1336164425. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.